Multiple S100A4 blocking antibodies have been reported and evaluated in preclinical models of breast cancer, prostate cancer, HCC, CRC, and skin fibrosis (49, 52, 65, 90, 117, 121). This evidence concerns the gene S100A4 and prostate cancer.